These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27712718)

  • 21. "Stick or Twist?" Negotiating Price and Data in an Era of Conditional Approval.
    Gladwell D; Bullement A; Cowell W; Patterson K; Strong M
    Value Health; 2020 Feb; 23(2):191-199. PubMed ID: 32113624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries.
    Efthymiadou O; Kanavos P
    Int J Technol Assess Health Care; 2021 Jan; 37():e31. PubMed ID: 33509311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving Access to High-Cost Technologies in the Asia Region.
    Mundy L; Trowman R; Kearney B
    Int J Technol Assess Health Care; 2019 Jan; 35(3):168-175. PubMed ID: 31122302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs.
    Rothery C; Claxton K; Palmer S; Epstein D; Tarricone R; Sculpher M
    Health Econ; 2017 Feb; 26 Suppl 1():109-123. PubMed ID: 28139090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Technology coverage decisions by health care plans and considerations by medical directors.
    Steiner CA; Powe NR; Anderson GF; Das A
    Med Care; 1997 May; 35(5):472-89. PubMed ID: 9140336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of technology assessment in health benefits coverage for medical devices.
    Braslow NM; Shatin D; McCarthy DB; Newcomer LN
    Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
    Barbieri M; Hawkins N; Sculpher M
    Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do changes in drug coverage policy point to an increased role for cost-effectiveness analysis in the USA?
    Chambers JD
    Pharmacoeconomics; 2014 Aug; 32(8):729-33. PubMed ID: 24859242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of orthopaedic research evidence on health financing in Australia.
    Hua M; Myers D; Host L
    Health Res Policy Syst; 2018 May; 16(1):36. PubMed ID: 29716606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coverage with Evidence Development: applications and issues.
    Trueman P; Grainger DL; Downs KE
    Int J Technol Assess Health Care; 2010 Jan; 26(1):79-85. PubMed ID: 20059784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro fertilization and multiple pregnancies: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(18):1-63. PubMed ID: 23074488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
    Nicod E
    Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of value of information: best informing research design and prioritization using current methods.
    Eckermann S; Karnon J; Willan AR
    Pharmacoeconomics; 2010; 28(9):699-709. PubMed ID: 20629473
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.